Skip to main content

Table 2 Significant changes in circulating and imaging biomarkers from pre-treatment to cycle 2 day 2

From: Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study

Biomarker type Biomarker name Mean difference from pre-treatment to C2D2 [95% CI] p-value
Circulating VEGF-C −0.932 [−1.333, −0.531] 0.0002
FGFb −0.866 [− 1.262, − 0.469] 0.0003
VEGF-A −0.788 [− 1.16, − 0.415] 0.0004
M65 − 0.57 [− 0.845, − 0.296] 0.0004
Ang2 − 0.722 [− 1.084, − 0.36] 0.0006
Ang1 − 0.723 [− 1.101, − 0.345] 0.0009
VEGF-D − 0.316 [− 0.489, − 0.143] 0.0014
CTCs − 1.313 [−2.074, − 0.552] 0.0021
PDGFbb −0.44 [− 0.74 - -0.14] 0.0070
IL8 −0.47 [− 0.82 - -0.12] 0.0124
VCAM-1 0.32 [0.07–0.58] 0.0149
E-selectin −0.3 [− 0.54 - -0.06] 0.0183
Imaging WTV (mm3) −0.523 [− 0.751, − 0.295] 0.0002
ETV (mm3) −0.56 [− 0.813, − 0.307] 0.0003
T1 (ms) − 0.144 [− 0.217, − 0.071] 0.0008
ADC (×10−3mm2/s) 0.01 [0.00–0.02] 0.0170
νe 0.04 [0.01–0.07] 0.0254
Ktrans (/min) 3.38 [0.05–6.70] 0.0469 *
  1. Biomarker measurements were all log2 transformed, except ADC and Ktrans which were multiplied by 100, and iAUC, νe, νp and EF which were not changed. Analysed using paired Student’s t-test to assess for statistical significance
  2. All circulating biomarkers measured in pg/ml. Imaging biomarkers are stated. νe has no units
  3. *Not statistically significant based on study cut-off of p value < 0.025
\